Rhinology and Sinus Surgery, Division of Otolaryngology, Department of Surgery, University of Calgary, Calgary, Alberta, Canada.
Laryngoscope. 2014 Jan;124(1):19-23. doi: 10.1002/lary.24135. Epub 2013 May 13.
OBJECTIVES/HYPOTHESIS: To define long-term health-state utility outcomes in patients undergoing endoscopic sinus surgery (ESS) for refractory chronic rhinosinusitis (CRS).
Prospective, longitudinal, cohort study.
The short-form (SF)-12 survey was issued to the 168 patients who were enrolled in an initial study evaluating short-term utility outcomes following ESS. SF-12 responses were converted into SF-6D utility scores using the University of Sheffield algorithm. The primary outcome was mean overall long-term utility level following ESS. Secondary outcomes evaluated annual utility level following ESS and utility outcomes for different subgroups of patients with CRS.
A total of 83 patients provided long-term health-state utility outcomes. The mean overall long-term utility level was 0.80 at a mean follow-up of 5.2 years after ESS. Compared to the baseline (0.67) and short-term follow-up (0.75) utility levels in this group, there was a significant improvement at the long-term period (P = .002). A total of 54% (45/83) of patients achieved long-term postoperative utility scores higher than the United States norm of 0.81. There was a significant improvement in utility scores for all subsequent years after ESS compared to preoperative responses (all P < .028). All subgroups of CRS received significant long-term utility improvements (all P < .001), and those undergoing revision ESS demonstrated continued improvement past the short-term postoperative period.
This study has demonstrated that patients with refractory CRS achieve stable mean long-term utility levels following ESS and often return to a health state comparable to US population norms.
目的/假设:定义内镜鼻窦手术(ESS)治疗难治性慢性鼻-鼻窦炎(CRS)患者的长期健康状态效用结果。
前瞻性、纵向、队列研究。
向最初评估 ESS 后短期效用结果的研究中纳入的 168 名患者发放简短形式(SF)-12 调查。使用谢菲尔德大学算法将 SF-12 应答转换为 SF-6D 效用评分。主要结局是 ESS 后平均总体长期效用水平。次要结局评估 ESS 后每年的效用水平以及不同 CRS 患者亚组的效用结果。
共有 83 名患者提供了长期健康状态效用结果。ESS 后平均 5.2 年的平均总体长期效用水平为 0.80。与该组基线(0.67)和短期随访(0.75)的效用水平相比,在长期期间有显著改善(P=0.002)。共有 54%(45/83)的患者获得了高于美国标准 0.81 的长期术后效用评分。与术前反应相比,ESS 后所有后续年份的效用评分均有显著改善(均 P<0.028)。所有 CRS 亚组均获得显著的长期效用改善(均 P<0.001),接受再次 ESS 的患者在短期术后期间持续改善。
本研究表明,难治性 CRS 患者在 ESS 后可获得稳定的平均长期效用水平,且经常恢复到与美国人群正常值相当的健康状态。